House of Lords written question – answered at on 9 July 2014.
To ask Her Majesty’s Government what advice the Clinical Priorities Advisory Group received about the routine use of Duodopa for advanced Parkinson's disease.
We understand that the Clinical Priorities Advisory Group considered evidence on the clinical effectiveness and estimated costs of Duodopa. NHS England plans to publish a commissioning policy statement for Duodopa in due course.
Yes0 people think so
No0 people think not
Would you like to ask a question like this yourself? Use our Freedom of Information site.